Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06549634 · ClinicalTrials.gov registry record
Biomarkers of AKI in Patients Receiving Daratumumab
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 20
- Enrollment target
NCT06549634 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 20 participants.
The verdict
NCT06549634 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
The goal of this prospective observational study is to understand changes in urinary and blood biomarkers associated with acute kidney injury (AKI) in patients newly diagnosed with multiple myeloma and being treated with Daratumumab SC. The aims of the study are: To measure changes in plasma and urinary biomarkers of AKI before initiation of Daratumumab therapy and 30 days after initiation of therapy. To establish whether these biomarkers serve to aid in early detection and prevention of AKI Participants will give urine and blood samples at their normally scheduled lab appointments.
Interventions
- DRUG Daratumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-09-01 |
| Est. Completion | 2026-01-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06549634
The ClinicalTrials.gov registry entry for NCT06549634 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Daratumumab is the first listed.
NCT06549634 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06549634 about?
NCT06549634 is a clinical study titled "Biomarkers of AKI in Patients Receiving Daratumumab". The goal of this prospective observational study is to understand changes in urinary and blood biomarkers associated with acute kidney injury (AKI) in patients newly diagnosed with multiple myeloma and being treated with Daratumumab SC. The aims of the study are: To measure changes in plasma and ur...
What is the current status of trial NCT06549634?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2024-09-01. Estimated completion is 2026-01-15.
What interventions are being tested in trial NCT06549634?
The interventions under investigation include: Daratumumab (DRUG).
Who is sponsoring clinical trial NCT06549634?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.